CALA News and Press, Calithera Biosciences Inc. From 09/25/19

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...

The following slide deck was published by Calithera Biosciences, Inc. in conjunction with this Read more ...

-Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late Breaking Oral Presentation- -Data from INCB001158 clinical program accepted as Oral Presentation- SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...

Calithera Biosciences, Inc. (CALA) Q2 2019 Earnings Conference Call August 08, 2019, 17:00 ET Company Participants Jennifer McNealey - VP, IR & Strategy Susan Molineaux - Co-Founder, CEO, President & Director Keith Orford - Chief Medical Officer Stephanie Wong - SVP, Fi...

Calithera Biosciences (NASDAQ: CALA ): Q2 GAAP EPS of -$0.58 beats by $0.07 . More news on: Calithera Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 8, 2019-- SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and develop...

I think resentment is when you take the poison and wait for the other person to die " - M.T., A Sponsorship Guide for 12-Step Programs Today, we take a look at a 'Busted IPO' from the biotech sector. The company's pipeline continues to slowly advance, and the stock has seen some insider b...

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today anno...

"The merit of all things lies in their difficulty." - Alexandre Dumas, The Three Musketeers We have kicked off the second half of 2019 with the S&P 500 at all-time highs after rallying some 17% so far this year. That is the best first half of performance for the index since 1997. One...